Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination allergenic product composed of pollen extracts from Morella cerifera (wax myrtle), Sequoia sempervirens (coast redwood), and Pinus banksiana (jack pine). These pollen extracts are primarily used for allergy testing and possibly for allergen-specific immunotherapy, to diagnose or desensitize individuals with sensitivities to these tree pollens. Morella cerifera and Pinus banksiana pollen extracts are documented as allergenic extracts used in clinical allergy testing. Pollen from these species can provoke allergic reactions including rhinitis, conjunctivitis, or asthma in sensitized individuals. There is no evidence for pharmaceutical or non-allergenic therapeutic use of this combination, nor of a unique brand or code-named formulation. Each pollen’s extract may also have traditional uses: Morella cerifera extract has traditional medicinal uses (digestive, antimicrobial, astringent), but not specifically from pollen[1][4][13][19][22]. Pinus banksiana pollen is used for allergy testing[15]. Sequoia sempervirens pollen allergies are known, but clinical documentation of pollen use for diagnostic/allergenic purposes is limited.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on morella cerifera pollen + sequoia sempervirens pollen + pinus banksiana pollen.